STERIS plc

▲ Bull Case

• ◆EtO EPA rules prove manageable via compliance paths (consistent with 2006 and 2019 precedent); capital equipment recovery confirmed in FY2026-FY2027; AST delivers 12-14%/yr organic growth; adj. EPS reaches $12.50-13.50 by FY2028 and multiple re-rates to 24x — implying a price of ~$312 and ~+48.6% total return including dividends (25% probability).
• ◆Hospital sterile processing switching costs create near-permanent customer lock-in: full SPD workflow revalidation costs $1-5M and 3-6 months, re-training and FDA/accreditation documentation make switching economically irrational, and STERIS earns 6-9% annual price increases with near-100% service contract renewal rates — a compounding moat built over 30+ years.
• ◆Capital equipment backlog recovery ($354M → $369M → $400M+) seeds FY2028-FY2029 recurring revenue acceleration: each dollar of capital equipment installed generates 7-10 years of service/consumable recurring revenue at 40-60% of original price annually, and a +8-10% capital equipment revenue inflection in FY2027 versus consensus +5% could add $300-500M to FY2028-FY2029 revenue — a 5-8% adj. EPS beat the sell-side has not fully modeled.

▼ Bear Case

• ◆EPA final EtO rule mandates closure of 5-7 STERIS facilities (breaking historical precedent of compliance paths over closures), hospital CapEx declines -5-10% YoY in FY2026-FY2027, adj. EPS stalls at ~$9.50-10.25, and multiple compresses to 18x — implying a price of ~$175 and a total return of approximately -15.7% including dividends (22% probability).
• ◆EtO regulatory risk is real and structurally underappreciated: EPA proposed stricter emission standards, and while FDA has formally intervened stating EtO is medically necessary for ~50 device categories, any break from the historical EPA-FDA dynamic could result in material AST revenue impairment — each facility closure represents ~2% of AST segment revenue with no short-term alternative modality replacement capacity.
• ◆Capital equipment recovery is uncertain in timing: hospital capital spending was soft in FY2023-FY2025 due to labor cost inflation and balance sheet pressure, and if two consecutive fiscal years of capital equipment revenue decline occur, the recurring revenue acceleration thesis for FY2028-FY2029 is delayed by 2-3 years, weighing on the multiple and earnings trajectory simultaneously.

“The central Wall Street debate is whether the 15-20% multiple discount to wide-moat healthcare peers is a genuine buying opportunity created by transient EtO regulatory fear and a delayed capital equipment cycle — or whether it reflects a structurally lower-quality earnings stream because EtO closures will prove more disruptive than the 2006/2019 precedents suggest and hospital CapEx recovery will be slower and shallower than the backlog implies. Bulls argue STERIS's 78% recurring revenue base, FDA intervention, and AST network irreplicability justify multiple re-rating as EtO risk resolves. Bears counter that the EtO overhang is binary and unresolvable until EPA final rulemaking, that capital equipment timing is inherently lumpy and unpredictable, and that 20-21x forward P/E leaves little margin of safety if either risk crystallizes. A secondary debate concerns the capital equipment backlog-to-recurring-revenue feedback loop: sell-side models do not fully capture the compounding effect of backlog growth on FY2028-FY2029 recurring revenue, which represents the most significant variant perception opportunity in the bull case.”

• ◆Q4 FY2026 earnings (May 2026) and FY2027 adj. EPS guidance — the most critical near-term data point for trajectory visibility
• ◆EPA final EtO rulemaking publication (Federal Register) — the most important binary event; outcome determines whether bear case or base case prevails
• ◆Capital equipment backlog progression toward $450M+ — confirmation of hospital CapEx recovery and FY2028-FY2029 recurring revenue acceleration
• ◆AST segment organic revenue growth sustaining ≥8% — confirmation that the highest-margin growth engine is intact and EtO disruption is contained
• ◆Hospital balance sheet normalization driving deferred SPD infrastructure investment — patient safety compliance creates non-discretionary capital equipment demand regardless of macro conditions
• ◆Restructuring savings realization ($40-50M annual benefits) flowing through to adj. EBITDA margin expansion in FY2027

• ◆EPA final EtO rule mandating closure of more than 3 STERIS facilities — breaks historical compliance-path precedent; each closure represents ~2% of AST revenue with no near-term alternative modality substitution
• ◆Capital equipment revenue declining in two consecutive fiscal years (FY2026 and FY2027) — signals hospital CapEx is structurally constrained, delaying recurring revenue acceleration by 2-3 years
• ◆AST segment organic growth falling below 4% for two consecutive quarters — signals EtO closures more disruptive than modeled or competitive pressure from Sotera Health intensifying
• ◆Net Debt/EBITDA rising above 2.5x from current ~1.1x — implies $2B+ incremental debt from a poorly-timed large acquisition or sharp FCF deterioration; could pressure investment-grade credit
• ◆Full-year adj. EPS growth falling below 5% — justifies multiple compression to 18-19x (slow-growth services) from current 20-21x; triggered by EtO restructuring costs, persistent capital equipment decline, FX headwinds, or managed care reimbursement pressure
• ◆Conference call transcripts unavailable — Q4 FY2026 management tone on FY2027 guidance, EtO regulatory commentary, and AST margin recovery timeline remain unvalidated pending re-run after Q1 FY2027 earnings (August 2026)